Coya Therapeutics (NASDAQ:COYA) Now Covered by D. Boral Capital

D. Boral Capital assumed coverage on shares of Coya Therapeutics (NASDAQ:COYA - Free Report) in a report released on Wednesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $15.00 target price on the stock.

Other analysts have also issued reports about the company. HC Wainwright reiterated a "buy" rating and set a $18.00 price target on shares of Coya Therapeutics in a report on Monday, November 11th. Chardan Capital restated a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Thursday, November 7th.

Coya Therapeutics Stock Performance

Coya Therapeutics stock traded up $0.05 during mid-day trading on Wednesday, reaching $6.09. The stock had a trading volume of 62,690 shares, compared to its average volume of 69,052. Coya Therapeutics has a fifty-two week low of $4.75 and a fifty-two week high of $10.69. The stock's 50-day simple moving average is $7.18 and its 200-day simple moving average is $6.80. The firm has a market capitalization of $101.76 million, a PE ratio of -9.29 and a beta of 0.26.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.15. On average, research analysts forecast that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Insider Activity at Coya Therapeutics

In related news, CEO Arun Swaminathan acquired 5,000 shares of the firm's stock in a transaction that occurred on Monday, November 11th. The shares were bought at an average cost of $7.34 per share, for a total transaction of $36,700.00. Following the purchase, the chief executive officer now owns 5,000 shares in the company, valued at $36,700. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have purchased 9,510 shares of company stock worth $69,615. 9.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Coya Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in COYA. Vanguard Group Inc. grew its position in Coya Therapeutics by 772.3% during the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company's stock worth $8,407,000 after buying an additional 750,338 shares in the last quarter. Gilbert & Cook Inc. purchased a new position in Coya Therapeutics during the second quarter worth about $61,000. Renaissance Technologies LLC purchased a new position in Coya Therapeutics during the second quarter worth about $101,000. GHP Investment Advisors Inc. purchased a new position in Coya Therapeutics during the third quarter worth about $169,000. Finally, Geode Capital Management LLC grew its position in Coya Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company's stock worth $918,000 after buying an additional 4,485 shares in the last quarter. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.